Post COVID-19 Pulmonary Fibrosis Management: A Systematic Review
Introduction Post-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly…
2024 1,480 reads 0 citations
Review Articles
Post COVID-19 Pulmonary Fibrosis Management: A Systematic Review
IntroductionPost-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly summarize all the different management and their possible outcomes.
MethodsThe databases that were searched included CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE to identify English language studies published up to October 5th, 2023.
ResultsInitially, the systematic search conducted brought 150 papers. Out of the 150, 13 of them were included in this study. A total of 662 patients were included in the study, all with different managements for COVID-19-induced pulmonary fibrosis. The mean age was 61.8 years. Many comorbidities were observed in patients with COVID-19-induced pulmonary fibrosis. Different treatment regimens were picked based on the different conditions of the patients but as far as antifibrotics go, Pirfenidone and Nintedanib were the most commonly used ones.
ConclusionBoth antifibrotics and steroids seemed to yield justifiable outcomes when used separately as well as when used in combination.
Keywords Covid-19 Pulmonary fibrosis Management Post-COVID Treatment All subjects
Barw Medical Journal. 2024